Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01228760
Other study ID # ASG-5ME-10-1
Secondary ID
Status Completed
Phase Phase 1
First received October 21, 2010
Last updated June 6, 2013
Start date October 2010
Est. completion date February 2013

Study information

Verified date June 2013
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this dose escalation study is to determine the Maximum Tolerated Dose (MTD) and the recommended Phase 2 dose of ASG-5ME in subjects with castration-resistant prostate cancer (CRPC).


Description:

The study has two components. The first aims to establish a safe dose of ASG-5ME. Once identified, the safety and preliminary estimate of antitumor activity of ASG-5ME will be tested in additional subjects with castration-resistant prostate cancer (CRPC) who are either chemotherapy naïve or chemotherapy exposed in expanded cohorts.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date February 2013
Est. primary completion date February 2013
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subject has histologically-confirmed castration-resistant prostate cancer and meets at least 1 of the following criteria:

- subject's disease has progressed on or after available standard therapy -OR-

- there is no effective standard therapy available for treating the subject's disease -OR-

- subject or his disease is not suitable for standard therapy -OR-

- subject chooses to defer or decline standard therapy (subject is adequately informed of the availability of clinically meaningful therapy and chooses instead to partake in this research using a product with no documented clinical activity)

- Testosterone = 50 ng/dL

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Life expectancy of > 6 months as evaluated and documented by the investigator

- Hematologic function, as follows (no red blood cell (RBC) or platelet transfusions are allowed within 4 weeks of the first dose of ASG-5ME):

- Absolute neutrophil count (ANC) = 1.5 x 109/L

- Platelet count = 100 x 109/L

- Hemoglobin = 9 g/dL

- Renal function, as follows: creatinine = 1.5 x upper limit of normal (ULN), or creatinine clearance of > 60 mL/min if serum creatinine is > 2.0 mg/dL

- Total bilirubin < 1. 5 x ULN

- Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT)= 1.5 x ULN

- International Normalized Ratio (INR) < 1.3 (or < 3.0 if on therapeutic anticoagulation)

- Serum calcium = ULN

- Subjects must be taking and agree to remain on a stable dose of luteinizing hormone-releasing hormone (LHRH) agonist therapy or gonadotropin-releasing hormone (GnRH) antagonist for the duration of the trial if not surgically castrated

- Additional Inclusion criteria for Chemotherapy Naïve Cohort: No prior systemic cytotoxic chemotherapies

- Additional Inclusion criteria for Chemotherapy Exposed Cohort:

- Documented disease progression during or after docetaxel treatment or intolerability to docetaxel treatment

- No additional prior chemotherapy for CRPC is allowed

Exclusion Criteria:

- History of central nervous system metastasis, including incompletely treated epidural disease

- History of other primary malignancy (including premalignant myeloid malignancy e.g. myelodysplastic syndrome), unless:

- Curatively resected non-melanomatous skin cancer

- Other malignancy curatively treated with no known active disease present and no treatment administered for the last 3 years

- Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 12 months of study enrollment, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by outsubject medication

- The following treatments are not allowed within 4 weeks of enrollment: cytotoxic chemotherapy, radiation therapy or the dietary supplement PC-SPES

- Use of prednisone (or equivalent corticosteroids) > 20 mg/day are not allowed. Doses < 20 mg/day are allowed only if they have been at the same dose for > 4 weeks

- Use of anti-androgen therapy (ie, flutamide, bicalutamide and nilutamide) within 6 weeks of study enrollment; non-responders to second-line anti-androgen therapy do not require the 6 week withdrawal period

- Monoclonal antibody therapy within 3 months of enrollment with the exception of denosumab (prior or concurrent use of denosumab is allowed)

- Peripheral neuropathy of = grade 2 as defined by the CTCAE criteria version 4.0

- Major surgery (that requires general anesthesia) within 4 weeks of study enrollment

- Active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of screening

- Use of any investigational drug (including marketed drugs not approved for this indication) within 30 days prior to enrollment

- History of thromboembolic events and bleeding disorders = 3 months (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE))

- Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B surface antigen

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
ASG-5ME
IV

Locations

Country Name City State
United States The Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland
United States The Karmanos Cancer Institute Detriot Michigan
United States University of Wisconsin Madison, Carbone Cancer Center Madison Wisconsin
United States Memorial Sloan Kettering Cancer Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
Astellas Pharma Inc Seattle Genetics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety assessed by recording of adverse events, laboratory assessments and vital signs For 12 weeks during treatment period and up to 4 weeks follow up No
Primary Pharmacokinetics assessment of ASG-5ME blood levels through analysis of blood samples Up to day 15 for cycle 1 and cycle 4 and pre-dose for cycles 2 and 3; every 3 weeks during the second 12 weeks of treatment; and if subject continues on study drug, every 12 weeks thereafter No
Secondary Incidence of anti-ASG-5ME antibody formation Baseline; up to day 64 during the first 12 weeks; and if subject continues on study drug, every 3 weeks during the second 12 weeks of treatment and every 12 weeks thereafter No
Secondary Incidence of tumor response (complete or partial response) Baseline and every 12 weeks while on study drug No
Secondary Changes in prostate-specific antigen (PSA) levels Baseline; up to day 64 during the first 12 weeks; and if the subject continues on study drug, every 3 weeks thereafter No
Secondary Changes in bone scans Baseline and every 12 weeks while on study drug No
Secondary Changes in circulating tumor cells Baseline; up to day 64 during the first 12 weeks; and if the subject continues on study drug, every 3 weeks during the second 12 weeks of treatment and every 12 weeks thereafter No
Secondary Changes in cytokeratin-18 levels Up to day 79 and 4 weeks after the last dose of study drug No
See also
  Status Clinical Trial Phase
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Completed NCT01400555 - A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 1
Terminated NCT03685591 - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Phase 1
Completed NCT00643617 - CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry N/A
Recruiting NCT01581749 - Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer Phase 4
Completed NCT01424930 - A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Completed NCT00544440 - An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma Phase 2
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Suspended NCT02759744 - Fusion Guided Focal Laser Ablation of Prostate Cancer N/A
Completed NCT00474383 - An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy Phase 2
Completed NCT01284920 - A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients Phase 1/Phase 2
Completed NCT02319239 - Prostate Cancer Stereotactic Radiotherapy N/A
Completed NCT00910754 - A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 1
Completed NCT00972309 - A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer Phase 1
Terminated NCT03531827 - Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment Phase 2
Completed NCT00167648 - Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer Phase 2
Not yet recruiting NCT05577689 - Novel Therapy Target in Metastatic Prostate Cancer
Enrolling by invitation NCT03173924 - 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer Phase 2
Completed NCT04703543 - Evaluating the Role of Both PSMA and 64Cu-PET/CT Total Body in Patients With Locally Relapsed Prostate Cancer N/A
Completed NCT01477749 - Sipuleucel-T Manufacturing Demonstration Study Phase 2